OrganOx metra System
Organox Limited · Decision date Dec 9, 2021
What did the FDA approve?
The FDA decision dated 2021-12-09 for OrganOx metra System (P200035) carries the action code APPR, with no supplement type or reason supplied in the record. The listed scope is the approved indication for a transportable device intended to sustain donor livers in a functioning state for a total preservation time of up to 12 hours, for grafts from donors after brain death (DBD) or from donors after circulatory death (DCD) aged 40 years or younger, with 20 minutes or less of functional warm ischemic time measured from donor systolic blood pressure below 50 mmHg, and macrosteatosis of 15% or less.
The record names a device category of normothermic machine perfusion for donor livers before transplantation, with product code QQK and applicant Organox Limited, under Gastroenterology and Urology. The statement describes a preservation purpose in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient; it does not report trial data, safety or effectiveness findings, or any additional indication beyond the wording given.
FDA approval order statement
Approval for the OrganOx metra System. The device is approved for the following indication: The OrganOx metra is a transportable device intended to be used to sustain donor livers destined for transplantation in a functioning state for a total preservation time of up to 12 hours.The OrganOx metra device is suitable for liver grafts from donors after brain death (DBD), or liver grafts from donors after circulatory death (DCD) <=40 years old, with <=20 mins of functional warm ischemic time (time from donor systolic blood pressure <50 mmHg), and macrosteatosis <=15%, in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 9, 2021
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200035
- Regulatory pathway
- Premarket approval application
- Applicant
- Organox Limited
- Product code
- QQK
- Decision code
- APPR
- Decision date
- Dec 9, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.
- Applicant
- Organox Limited
- Product code
- QQK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200035 received
Application receipt date recorded by FDA.
P200035 · FDA decision
APPR
P200035/S038 · Related supplement
OrganOx metra System
Timeline entries are records held by MedtechLedger for P200035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
OrganOx metra SystemP200035/S038 | Organox Limited | PMA supplement | Oct 9, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Organox Limited
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Oxford Science Park, Magdalen Centre, Robert Robinson Ave., Oxford, OX4 4GA
Sources and methodology
- Original FDA record: P200035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records